SCHEMBL19437263

SCHEMBL19437263

CCOC(=O)c1cc(C(=O)NC)c2oc(C)c(-c3cccc(OCc4ccccc4)c3)c2c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 1/20 0.46
▸ JAK3 P52333 1/20 0.46
▸ MAOB P27338 3/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ HSP90AA1 P07900 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ PPARG P37231 1/20 0.41
▸ PTGER4 P35408 1/20 0.41
▸ NR1H2 P55055 1/20 0.41
▸ NR1H4 Q96RI1 1/20 0.40
▸ MAPT P10636 2/20 0.40
▸ SMPD1 P17405 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ MRGPRX4 Q96LA9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28692716 0.91 NR1H4 (0.47) MAOBMEN1KMT2APTGER4NR1H2
SCHEMBL19437381 0.89 L3MBTL1 (0.41) MEN1KMT2ANR1H2MAPTL3MBTL1
SCHEMBL28933660 0.80 NR1H4 (0.39) KMT2APPARGPTGER4NR1H2NR1H4
SCHEMBL21649772 0.75 LMNA (0.39) MAOBPTGER4NR1H2ALDH1A1SMN1; SMN2
SCHEMBL3911336 0.74 MRGPRX4 (0.62) JAK2JAK3MAOBMEN1HSP90AA1
SCHEMBL6177306 0.73 CYSLTR1 (0.57) JAK2JAK3MAOBMEN1HSP90AA1
SCHEMBL20876256 0.72 MEN1 (0.41) MEN1KMT2AMAPTL3MBTL1NPC1
SCHEMBL19437420 0.72 KMT2A (0.41) MAOBMEN1KMT2AMAPTNPC1
SCHEMBL21649780 0.72 BRD4 (0.46) —
SCHEMBL340106 0.71 MAOB (0.69) MAOBMEN1HSP90AA1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108884083-B Benzo [ B ] furans as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2022-02-25 — — CN disclosed
US-10583112-B2 Benzo[b]furans as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2020-03-10 — — US disclosed
EP-3440075-B1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2020-01-29 — — EP disclosed
EP-3440075-B1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2020-01-29 — — EP disclosed
US-20190151279-A1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-05-23 — — US disclosed
US-20190151279-A1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2019-05-23 — — US disclosed
EP-3440075-A1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) 2019-02-13 — — EP disclosed
WO-2017174620-A1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-10-12 — — WO disclosed
WO-2017174620-A1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-10-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10583112-B2 Benzo[b]furans as bromodomain inhibitors BRD4, BRD3, BRD2 JAK2 596/4885JAK3 2260/4885MAOB 201/4885
US-20190151279-A1 BENZO[B]FURANS AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD2 JAK2 596/4885JAK3 2260/4885MAOB 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback